Meta-Analysis Found CBD and THC Had Trivial Effects on Blood Inflammation Markers
A meta-analysis of 13 clinical studies found that CBD and THC produced small, statistically insignificant changes in circulating inflammatory markers (IL-6, IL-8, IL-10, TNF-alpha), challenging the widely promoted anti-inflammatory claims.
Quick Facts
What This Study Found
Pooled estimates showed trivial and imprecise effects: IL-6 (SMD -0.17, p=0.41), IL-8 (SMD -0.30, p=0.06), IL-10 (SMD -0.10, p=0.79), and TNF-alpha (SMD -0.09, p=0.62). None reached statistical significance. Some individual trials in high-exposure or diseased populations reported reductions, but pooled effects were negligible. GRADE evidence certainty ranged from very low to moderate.
Key Numbers
IL-6: SMD -0.17 (CI: -0.56 to 0.23, p=0.41, I2=55%, n~129/arm); IL-8: SMD -0.30 (CI: -0.62 to 0.01, p=0.06, I2=0%, n~78/arm); IL-10: SMD -0.10 (CI: -0.83 to 0.63, p=0.79, I2=81%, n~92/arm); TNF-alpha: SMD -0.09 (CI: -0.45 to 0.27, p=0.62, I2=33%, n~105/arm); GRADE: very low to moderate
How They Did This
Systematic review and meta-analysis of 13 clinical studies meeting inclusion criteria. Random-effects models calculated standardized mean differences. Risk of bias assessed with RoB-2. Evidence certainty graded using GRADE methodology.
Why This Research Matters
CBD and THC are widely marketed as anti-inflammatory, often based on preclinical data. This meta-analysis of actual human clinical trials shows that the anti-inflammatory effects observed in cells and animals have not consistently translated to measurable changes in human blood markers.
The Bigger Picture
The disconnect between strong preclinical anti-inflammatory evidence and trivial clinical effects raises important questions about dosing, bioavailability, and whether circulating markers capture the relevant anti-inflammatory activity of cannabinoids, which may be more localized.
What This Study Doesn't Tell Us
Only 13 studies met inclusion criteria with small sample sizes per meta-analysis, heterogeneous populations and dosing regimens, circulating biomarkers may not reflect tissue-level inflammation, GRADE certainty was low for several outcomes, publication bias possible
Questions This Raises
- ?Are circulating biomarkers the right measure for cannabinoid anti-inflammatory effects?
- ?Would higher doses or specific formulations produce stronger effects?
- ?Does the anti-inflammatory action occur locally rather than systemically?
Trust & Context
- Key Stat:
- Pooled effects of cannabinoids on all four inflammatory markers were trivial and non-significant
- Evidence Grade:
- Systematic review with meta-analysis and GRADE assessment; limited by small number of eligible studies and heterogeneous designs
- Study Age:
- Published 2025
- Original Title:
- The Pleiotropic Influence of Cannabidiol and Tetrahydrocannabinol on Inflammatory Biomarkers: A Systematic Review and Meta-Analytical Synthesis.
- Published In:
- International journal of molecular sciences, 26(23) (2025)
- Authors:
- Candeloro, Bruno Moreira, de Oliveira, Camila M, Gimenez, Fabiana Veronez Martelato, Barbosa, Marianne P C N, Soares, Beatriz Paiva, Ruiz, Ana C F, Folegatti, Derfel R M A, Barbalho, Sandra Maria, Oliveira, Nancy S, Porto, Andrey A, Garner, David Matthew, Sousa, Fernando H, Valenti, Vitor E
- Database ID:
- RTHC-06153
Evidence Hierarchy
Combines results from multiple studies to find an overall pattern.
What do these levels mean? →Frequently Asked Questions
Is CBD really anti-inflammatory?
In lab studies, yes. But this meta-analysis of 13 human clinical trials found trivial, non-significant effects on four major blood inflammatory markers. The strong preclinical evidence has not yet translated to consistent measurable changes in humans.
Why might CBD work in the lab but not in blood tests?
Several possibilities: CBD may work locally rather than systemically, blood markers may not capture the relevant anti-inflammatory activity, doses used in clinical trials may be insufficient, or CBD's low and variable bioavailability may limit its effects.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-06153APA
Candeloro, Bruno Moreira; de Oliveira, Camila M; Gimenez, Fabiana Veronez Martelato; Barbosa, Marianne P C N; Soares, Beatriz Paiva; Ruiz, Ana C F; Folegatti, Derfel R M A; Barbalho, Sandra Maria; Oliveira, Nancy S; Porto, Andrey A; Garner, David Matthew; Sousa, Fernando H; Valenti, Vitor E. (2025). The Pleiotropic Influence of Cannabidiol and Tetrahydrocannabinol on Inflammatory Biomarkers: A Systematic Review and Meta-Analytical Synthesis.. International journal of molecular sciences, 26(23). https://doi.org/10.3390/ijms262311618
MLA
Candeloro, Bruno Moreira, et al. "The Pleiotropic Influence of Cannabidiol and Tetrahydrocannabinol on Inflammatory Biomarkers: A Systematic Review and Meta-Analytical Synthesis.." International journal of molecular sciences, 2025. https://doi.org/10.3390/ijms262311618
RethinkTHC
RethinkTHC Research Database. "The Pleiotropic Influence of Cannabidiol and Tetrahydrocanna..." RTHC-06153. Retrieved from https://rethinkthc.com/research/candeloro-2025-the-pleiotropic-influence-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.